Gilead Names Executive to Lead Clinical Development of Co's Inflammation Programs
June 01 2020 - 07:09PM
Dow Jones News
By Stephen Nakrosis
Gilead Sciences Inc. said Monday it named Mark Genovese to
oversee the clinical development of its investigational portfolio
of treatments for inflammatory conditions.
Dr. Genovese comes to Gilead from Stanford University, where he
was on the faculty for more than 21 years and most recently served
as the James W. Raitt Professor of Medicine and Clinical Chief in
the Division of Immunology and Rheumatology, the company said.
Dr. Genovese, who was named as the company's SVP, Inflammation,
will have responsibility "for the company's fibrosis clinical
research programs including nonalcoholic steatohepatitis,
idiopathic pulmonary fibrosis and systemic sclerosis," the company
said.
Gilead said it is expanding its work in the field of
inflammatory diseases, and added it has filed for regulatory
approval in the U.S., Europe and Japan "of a potential treatment
for rheumatoid arthritis, which, if approved, would be the
company's first medicine to treat an inflammatory disease."
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
June 01, 2020 18:54 ET (22:54 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.